New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 12, 2017 – The FDA announced a Class II recall of one lot of Kalbitor (ecallantide) injection due to the presence of glass particulate matter.
Download PDF
Return to publications
